Last reviewed · How we verify
14C-LY2140023
14C-LY2140023 is a Diagnostic/radiolabeled tracer compound Small molecule drug developed by Denovo Biopharma LLC. It is currently in Phase 1 development.
Radiolabeled prodrug that is converted to LY404039, an agonist of metabotropic glutamate 2/3 receptors.
14C-LY2140023 is a small molecule that acts as a metabotropic glutamate receptor 2 agonist. It was studied in a clinical trial (NCT01637142) to determine its absolute bioavailability in healthy participants.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | 14C-LY2140023 |
|---|---|
| Sponsor | Denovo Biopharma LLC |
| Drug class | Diagnostic/radiolabeled tracer compound |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
LY2140023 is a prodrug that is metabolized to the active moiety LY404039, which selectively activates metabotropic glutamate 2 and 3 (mGlu2/3) receptors. The 14C radiolabel allows tracking of drug distribution and metabolism in pharmacokinetic studies.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14C-LY2140023 CI brief — competitive landscape report
- 14C-LY2140023 updates RSS · CI watch RSS
- Denovo Biopharma LLC portfolio CI
Frequently asked questions about 14C-LY2140023
What is 14C-LY2140023?
How does 14C-LY2140023 work?
Who makes 14C-LY2140023?
What drug class is 14C-LY2140023 in?
What development phase is 14C-LY2140023 in?
Related
- Drug class: All Diagnostic/radiolabeled tracer compound drugs
- Manufacturer: Denovo Biopharma LLC — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing